As SATB2/CBP plays critical roles in promoting GSC proliferation and GBM growth, we next explore whether pharmacologic inhibition of CBP activity by a small molecule inhibitor named C646 (Bowers et al, 2010) could impact GSC‐driven tumor growth. The gene discussed is SATB2; the disease is glioblastoma.